Jennison Associates
CORT icon

Jennison Associates’s Corcept Therapeutics CORT Stock Holding History

Jennison Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,151,617
Closed -$9.38M – 718
2014
Q1 		$9.38M Buy
2,151,617
+6,875
+0.3% +$24K 0.01% 489
2013
Q4 		$6.91M Buy
2,144,742
+7,993
+0.4% +$16.2K 0.01% 500
2013
Q3 		$3.4M Hold
2,136,749
– – ﹤0.01% 526
2013
Q2 		$3.7M Buy
+2,136,749
New +$3.84M ﹤0.01% 501

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

Jennison Associates's CORT Position: Q2 2014 in Review

Jennison Associates sold out of Corcept Therapeutics (CORT) in Q2 2014, closing a stake of 2,151,617 shares — an estimated $9.38M sold.

Jennison Associates first reported a position in CORT in Q2 2013 and held it in 4 quarters. The position peaked at $9.38M in Q1 2014. 62 funds tracked by Wall St. Rank hold CORT as of Q2 2014.

  • Jennison Associates reported no remaining Corcept Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Jennison Associates sold 2,151,617 Corcept Therapeutics shares in Q2 2014, an estimated $9.38M.
  • Jennison Associates first reported a position in Corcept Therapeutics in Q2 2013 and held it in 4 quarters.
  • Jennison Associates's Corcept Therapeutics position peaked at $9.38M in Q1 2014.
  • 62 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2014.

Based on Jennison Associates's 13F filing for Q2 2014, filed 8 Aug 2014.